Takahashi K, Shibata T, Akashi-Takamura S, Kiyokawa T, Wakabayashi Y, Tanimura N, et al
Patients with HT who received replacement with levothyroxine (L-T4) did not always achieve clinically significant results, which requires additional therapeutic agents ( The significant prevalence of AITD, a long latent period and the involvement of autoimmune processes in their occurrence, development of concomitant diseases, insufficient effectiveness of the main pharmacotherapy, and a decrease in the quality of life of patients require the development of adequate approaches for the correction of immune processes in order to prevent and treat diseases
R., Furne, J., Stoltz, G
Scientific Activity The blend has no single unified target
Consumers are no longer waiting until something feels off to start paying attention to their health
Physiological levels of ATP negatively regulate proteasome function